Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 64% · prior close shown (market closed)
BridgeBio Pharma, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +67% YoY in Q1 FY2026.
Priority: CALIBRATE..
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
Reported figures for BridgeBio Pharma, Inc. — research only, not investment advice.
Updated
What happened recently for BridgeBio Pharma, Inc. (BBIO) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$79.86
Market cap
$15.61B
Profitable
No
Revenue $194.50M
Net income
$-166.56M
FY Jul 16, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for BridgeBio Pharma, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
Follow BridgeBio Pharma, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.